About 9,500 American men are diagnosed with testicular cancer each year, and although the absolute number is small compared with prostate or lung cancer, it is the most common solid tumor in men aged 15 to 35. Testicular cancer also has one of the highest cure rates in oncology, with five-year relative survival around 95 percent across all stages combined. Catching it early matters, because localized disease has survival rates exceeding 99 percent, while metastatic disease still does well but demands more aggressive treatment.
What Testicular Cancer Is
The vast majority of testicular cancers (over 95 percent) arise from germ cells, the cells that produce sperm. Germ cell tumors split into two broad categories with different biology and treatment: seminomas and non-seminomas. Seminomas tend to grow more slowly and are exquisitely sensitive to radiation and chemotherapy. Non-seminomas (embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, and mixed tumors) often spread earlier and require chemotherapy. According to the National Cancer Institute, age distribution differs slightly: seminomas peak in the 30s and 40s, non-seminomas in the late teens through 30s.
Non-germ cell tumors (Leydig and Sertoli cell tumors, lymphoma) account for the remaining minority and have different management. Risk factors include cryptorchidism (undescended testes, even after surgical correction), family history (a brother with testicular cancer raises lifetime risk roughly 8 to 10 fold), prior testicular cancer in the contralateral testicle, and certain genetic syndromes.
Symptoms
The most common presentation is a painless lump or swelling in one testicle, often noticed during a shower or while changing. Some men describe a feeling of heaviness or aching in the scrotum. About 10 percent of men have acute pain, sometimes from rapid tumor growth or hemorrhage within the tumor. Less commonly, men present with back or abdominal pain from retroperitoneal lymph node metastases, breathing difficulty from pulmonary metastases, gynecomastia from beta-hCG-producing tumors, or supraclavicular lymphadenopathy.
Many testicular masses turn out to be benign conditions like hydrocele, spermatocele, varicocele, or epididymitis. Distinguishing them requires examination and imaging, not self-diagnosis.
How It Is Diagnosed
Evaluation starts with bimanual scrotal examination, often performed in a warm room to relax the scrotum. Suspicious findings prompt scrotal ultrasound, which differentiates intratesticular from extratesticular masses with high accuracy. Intratesticular masses are presumed cancerous until proven otherwise.
Tumor markers (AFP, beta-hCG, and LDH) are drawn before any procedure. AFP elevation suggests non-seminomatous components (yolk sac or embryonal). Beta-hCG can elevate in either seminoma or non-seminoma. LDH correlates with tumor burden. Markers are repeated after orchiectomy to assess residual disease.
The diagnostic and initial therapeutic step is radical inguinal orchiectomy, removing the entire testicle through a groin incision rather than a scrotal one to avoid disturbing lymphatic drainage. Trans-scrotal biopsy is contraindicated because it can spread cancer along non-standard lymphatic pathways. Pathology confirms histology and assesses for lymphovascular invasion, rete testis involvement, and tumor size.
Staging includes CT of the abdomen, pelvis, and chest. The TNM and AJCC staging system divides disease into Stage I (confined to testicle), Stage II (retroperitoneal nodes), and Stage III (distant metastases or markedly elevated markers). Risk classification within Stage III uses the IGCCCG system.
Treatment by Stage and Histology
Stage I Seminoma
After orchiectomy, options include active surveillance (most common today), single-agent carboplatin chemotherapy, or limited radiation. Surveillance avoids treatment toxicity in the 80 to 85 percent who never relapse. According to NCCN guidelines, surveillance is preferred for most Stage I seminomas with appropriate follow-up imaging and markers.
Stage I Non-Seminoma
Surveillance, retroperitoneal lymph node dissection (RPLND), or one to two cycles of BEP chemotherapy are options based on lymphovascular invasion and patient preference. Surveillance is increasingly favored when reliable follow-up is possible.
Stage II
Stage II seminoma is treated with radiation or chemotherapy depending on bulk. Stage II non-seminoma usually receives 3 to 4 cycles of BEP (bleomycin, etoposide, cisplatin) chemotherapy, sometimes followed by post-chemotherapy RPLND for residual masses.
Stage III
Three to four cycles of BEP chemotherapy is standard, with intensified regimens for poor-risk disease. Salvage chemotherapy and high-dose chemotherapy with stem cell rescue are options for relapse. Even metastatic testicular cancer is curable in most cases.
Fertility and Long-Term Issues
Sperm banking before orchiectomy or chemotherapy is offered routinely. Many men have abnormal pre-treatment semen parameters even without overt fertility problems. Chemotherapy, especially platinum-based regimens, can cause temporary or permanent decreases in sperm production. The male infertility guide and semen analysis guide cover related fertility planning.
Long-term survivors face elevated risks of cardiovascular disease, secondary cancers, hypogonadism, neuropathy, and renal dysfunction depending on treatment received. The medical conditions library covers related survivorship topics. Surveillance schedules continue for 5 to 10 years post-treatment.
When to See a Doctor
Any new testicular mass, persistent scrotal swelling, or unexplained scrotal heaviness warrants prompt evaluation. The testicular self-exam guide covers what to feel for and how often. New back or abdominal pain in a young man, particularly with weight loss or breathing changes, should also prompt evaluation.
When to seek emergency care: Call 911 or go to the nearest emergency room if you experience sudden severe testicular pain (testicular torsion is a 6-hour surgical emergency), severe shortness of breath, hemoptysis, severe back pain with leg weakness, or signs of severe bleeding from a known tumor.
Frequently Asked Questions
What does testicular cancer feel like?
Most often it presents as a painless, firm, pea-sized to walnut-sized lump on or within the testicle. The mass is usually fixed to the testicle rather than separate. Some men describe a feeling of heaviness or aching in the affected side.
Can I have children after testicular cancer?
Many men father children after treatment, especially after orchiectomy alone. Chemotherapy and radiation can impair fertility temporarily or permanently. Sperm banking before treatment preserves options.
Is testicular cancer always treated by removing the testicle?
For confirmed cancers, yes. Radical inguinal orchiectomy is the standard initial treatment. Partial orchiectomy is occasionally considered for very small lesions in selected patients but is not the routine approach.
Will I need testosterone replacement after treatment?
Removing one testicle leaves the other to produce testosterone, and most men maintain normal levels. Men with bilateral disease, prior contralateral atrophy, or chemotherapy-induced damage may develop hypogonadism requiring replacement.
The Bottom Line
Testicular cancer is one of the most curable solid tumors in oncology, but cure depends on prompt evaluation of any testicular abnormality. Monthly self-examination starting at puberty, a low threshold to see a urologist for new lumps, and treatment at experienced centers all matter. The 95 percent five-year survival rate reflects how much modern chemotherapy and surveillance protocols have transformed what was once a routinely fatal disease.